Utilising multi-omics analysis and experimental validation, this study elucidates ACSL3’s dual function in the evolution of NAFLD-HCC and suggests targeting MEF2D or ACSL3 as a novel approach to counteract sorafenib resistance, offering potential translational significance (Table 1). Here, ACSL3 is linked to metabolic dysfunction-associated steatotic liver disease.